Adaptive Biotechnologies (ADPT) Gains from Sales and Divestitures (2019 - 2026)

Adaptive Biotechnologies has disclosed Gains from Sales and Divestitures across 8 years of filings, most recently posting $1.4 million for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $1.4 million, down 52.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 52.93% YoY), and the FY2025 annual result was $247117.0, down 90.45% from the prior year.
• Gains from Sales and Divestitures came in at $1.4 million for Q1 2026 at Adaptive Biotechnologies, up from $247117.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $3.0 million in Q1 2025 to a low of $141185.0 in Q1 2022.
• The 5-year median for Gains from Sales and Divestitures is $1.2 million (2023), against an average of $1.2 million.
• Across the five-year window, Gains from Sales and Divestitures surged 1524.73% in 2022 and plunged 90.45% in 2025, its largest moves.
• Adaptive Biotechnologies' Gains from Sales and Divestitures stood at $304637.0 in 2022, then soared by 394.64% to $1.5 million in 2023, then jumped by 71.73% to $2.6 million in 2024, then slumped by 90.45% to $247117.0 in 2025, then jumped by 474.0% to $1.4 million in 2026.
• The last three Gains from Sales and Divestitures figures came in at $1.4 million (Q1 2026), $247117.0 (Q4 2025), and $247117.0 (Q3 2025), per Business Quant data.